PROK
NASDAQ · Biotechnology
Prokidney Corp
$1.80
+0.03 (+1.69%)
Financial Highlights (FY 2026)
Revenue
2.08M
Net Income
-159,930,405
Gross Margin
—
Profit Margin
-7,725.2%
Rev Growth
—
D/E Ratio
0.00
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | 60.2% | 60.2% | 60.2% |
| Operating Margin | -18,477.8% | 32.7% | 26.5% | 28.9% |
| Profit Margin | -7,725.2% | 20.9% | 25.1% | 26.1% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 2.08M | 45.98M | 42.93M | 40.88M |
| Gross Profit | — | 27.67M | 25.84M | 24.60M |
| Operating Income | -384,458,415 | 15.03M | 11.39M | 11.82M |
| Net Income | -159,930,405 | 9.61M | 10.78M | 10.68M |
| Gross Margin | — | 60.2% | 60.2% | 60.2% |
| Operating Margin | -18,477.8% | 32.7% | 26.5% | 28.9% |
| Profit Margin | -7,725.2% | 20.9% | 25.1% | 26.1% |
| Rev Growth | — | +20.4% | +3.7% | +1.7% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 1.02M | 212.35M | 210.18M | 232.91M |
| Total Equity | 275.37M | 340.13M | 367.41M | 326.92M |
| D/E Ratio | 0.00 | 0.62 | 0.57 | 0.71 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -367,312,008 | 17.18M | 13.92M | 13.69M |
| Free Cash Flow | — | 13.69M | 9.06M | 12.18M |